BMO Capital Markets Lowers Aveanna Healthcare (NASDAQ:AVAH) Price Target to $10.00

Aveanna Healthcare (NASDAQ:AVAH) had its price objective lowered by analysts at BMO Capital Markets from $11.00 to $10.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective suggests a potential upside of 53.37% from the stock’s previous close.

Several other research analysts also recently weighed in on AVAH. UBS Group upped their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Barclays upped their target price on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. William Blair started coverage on shares of Aveanna Healthcare in a research note on Monday, December 8th. They set an “outperform” rating for the company. Finally, Royal Bank Of Canada lifted their price target on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a report on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.81.

Aveanna Healthcare Stock Performance

NASDAQ:AVAH opened at $6.52 on Friday. The stock has a 50-day moving average price of $7.84 and a 200 day moving average price of $8.49. The stock has a market capitalization of $1.36 billion, a P/E ratio of 6.39 and a beta of 2.07. Aveanna Healthcare has a 12-month low of $3.73 and a 12-month high of $10.32. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39.

Insider Buying and Selling at Aveanna Healthcare

In related news, insider Edwin C. Reisz sold 60,769 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $438,144.49. Following the sale, the insider owned 1,447,057 shares in the company, valued at approximately $10,433,280.97. The trade was a 4.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Deborah Stewart sold 11,181 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $80,615.01. Following the sale, the chief accounting officer directly owned 301,807 shares in the company, valued at approximately $2,176,028.47. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 998,595 shares of company stock worth $7,567,770. Company insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Aveanna Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC raised its position in shares of Aveanna Healthcare by 21.2% during the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after buying an additional 4,602 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Aveanna Healthcare by 8.3% in the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after acquiring an additional 25,974 shares in the last quarter. Jane Street Group LLC grew its position in Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock worth $407,000 after acquiring an additional 63,010 shares in the last quarter. Creative Planning increased its stake in Aveanna Healthcare by 15.1% during the second quarter. Creative Planning now owns 47,025 shares of the company’s stock worth $246,000 after acquiring an additional 6,171 shares during the last quarter. Finally, Intech Investment Management LLC increased its stake in Aveanna Healthcare by 35.4% during the second quarter. Intech Investment Management LLC now owns 24,718 shares of the company’s stock worth $129,000 after acquiring an additional 6,469 shares during the last quarter. 87.96% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q4 results beat consensus — revenue grew strongly year‑over‑year and the company topped EPS and revenue estimates, providing fundamental support for the stock. Press Release
• Positive Sentiment: Raymond James upgraded AVAH to “strong-buy” and set a $13 price target, which is a bullish catalyst and likely helping intraday buying interest. Finviz item
• Neutral Sentiment: BMO trimmed its price target from $11 to $10 but maintained an “outperform” rating — a modest pullback in upside but not a negative rating change. Benzinga
• Neutral Sentiment: Aveanna issued 2026 guidance and a growth outlook; the details are being parsed by investors and helped explain the mixed market reaction (earnings beat vs. cautious forward commentary). TipRanks
• Neutral Sentiment: Reported short‑interest entries show anomalous “0 shares”/NaN data for March (data likely erroneous), so short‑interest signals are not meaningful right now.
• Negative Sentiment: Truist lowered its price target to $9 and moved to a “hold” rating, reducing analyst support and putting downside pressure on the stock. Benzinga
• Negative Sentiment: Market headlines flagged that Aveanna’s revenue outlook/trend in guidance trailed some consensus expectations, which prompted a pullback in some coverage and weighed on sentiment. MSN

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.